Market closed
Atossa Therapeutics/$ATOS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Atossa Therapeutics
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Ticker
$ATOS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
12
Website
ATOS Metrics
BasicAdvanced
$121M
Market cap
-
P/E ratio
-$0.21
EPS
1.23
Beta
-
Dividend rate
Price and volume
Market cap
$121M
Beta
1.23
52-week high
$2.31
52-week low
$0.72
Average daily volume
959K
Financial strength
Current ratio
13.304
Quick ratio
12.9
Management effectiveness
Return on assets (TTM)
-20.35%
Return on equity (TTM)
-31.30%
Valuation
Price to book
1.65
Price to tangible book (TTM)
1.65
Price to free cash flow (TTM)
-6.182
Growth
Earnings per share change (TTM)
-9.15%
3-year earnings per share growth (CAGR)
-11.60%
What the Analysts think about ATOS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Atossa Therapeutics stock.
ATOS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ATOS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ATOS News
AllArticlesVideos
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
GlobeNewsWire·2 weeks ago
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
GlobeNewsWire·2 weeks ago
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Atossa Therapeutics stock?
Atossa Therapeutics (ATOS) has a market cap of $121M as of December 24, 2024.
What is the P/E ratio for Atossa Therapeutics stock?
The price to earnings (P/E) ratio for Atossa Therapeutics (ATOS) stock is 0 as of December 24, 2024.
Does Atossa Therapeutics stock pay dividends?
No, Atossa Therapeutics (ATOS) stock does not pay dividends to its shareholders as of December 24, 2024.
When is the next Atossa Therapeutics dividend payment date?
Atossa Therapeutics (ATOS) stock does not pay dividends to its shareholders.
What is the beta indicator for Atossa Therapeutics?
Atossa Therapeutics (ATOS) has a beta rating of 1.23. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.